T.S. Wiley on Bio-identical Hormone Replacement Therapy for Patients With Breast Cancer

Video

T.S. Wiley, CEO, Wiley Protocol Systems, discusses a study that examined the efficacy of biomemetic bio-identical hormone replacement therapy for patients with metastatic breast cancer.

T.S. Wiley, CEO, Wiley Protocol Systems, discusses a study that examined the efficacy of biomemetic bio-identical hormone replacement therapy for patients with metastatic breast cancer.

Due to treatments that frequently block the estrogen receptor, several patients with breast cancer experience a change in hormonal status and a significant decrease in quality of life. Wiley discusses a study that examined between 57 and 112 women with breast cancer receiving biomemetic bio-identical hormone replacement therapy.

Results showed that these patients experienced a higher quality of life, Wiley says, mentioning a patient with triple-negative breast cancer who has been on the therapy for 10 years.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD
Ruben Olivares, MD